GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells therapies for immunology, announced it has closed on a Series A financing generating immediate proceeds of $157 million, led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children’s Research Institute.
August 11, 2021
· 3 min read